Results 31 to 40 of about 4,524 (132)

Detection of JAK2V617F tyrosine kinase mutation and estimation of serum erythropoietin in blood donors who have high hematocrit

مجلة كلية الطب, 2015
Background: JAK2V617F mutation is the most prevalent molecular abnormality in myeloproliferative neoplasms (MPNs) and has become a valuable marker for diagnosis of MPNs. Almost all patients with polycythemia vera (PV) have this acquired mutation. However,
Haythem A. AL-Rubaie, May A. Khudeir, Israa M Al-Bayaa   +2 more
doaj   +1 more source

Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow

Haematologica, 2012
We investigated 15,542 patients with suspected BCR-ABL1- negative myeloproliferative or myelodysplastic/myeloproliferative neoplasm (including 359 chronic myelomonocytic leukemia) by a molecular marker set.
Susanne Schnittger, Ulrike Bacher, Christiane Eder, Frank Dicker, Tamara Alpermann, Vera Grossmann, Alexander Kohlmann, Wolfgang Kern, Claudia Haferlach, Torsten Haferlach   +9 more
doaj   +1 more source

Neutrophil Extracellular Traps in Atherosclerosis and Cardiovascular Disease

MedComm, Volume 7, Issue 10, October 2026.
NETs as integrated effectors in the atherosclerotic cardiovascular disease continuum. Activated neutrophils release NETs that promote endothelial injury, thrombo‐inflammation, and plaque destabilization throughout atherosclerotic disease progression. Created with BioRender.com.
Ji Zhang, Fangjiaqi Wei, Mengdi Qu, Yuwen Shao, Tingye Xu, Darko Stojkov, Hans‐Uwe Simon, Ben Huang, Changhong Miao, Hao Zhang   +9 more
wiley   +1 more source

JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate

Haematologica, 2014
Clinical significance of the JAK2V617F mutation in patients with a myeloproliferative neoplasm has been the target of intensive research in recent years. However, there is considerably uncertainty about prognosis in JAK2V617F positive individuals without
Camilla Nielsen, Stig E. Bojesen, Børge G. Nordestgaard, Klaus F. Kofoed, Henrik S. Birgens   +4 more
doaj   +1 more source

Mutant NPM1 in Acute Myeloid Leukemia Initiation and Maintenance

Aging and Cancer, Volume 7, Issue 3, Page 109-124, September 2026.
NPM1 mutations drive acute myeloid leukemia by acting as neomorphic transcriptional regulators that cooperate with Menin–MLL and XPO1 to sustain HOX/MEIS1 expression and block differentiation. Targeting these mutant‐specific transcriptional dependencies provides a rational therapeutic strategy for NPM1‐mutated AML.
Yanan Jiang, Zhong Fan, Runmeng Liu, Xiaotian Zhang   +3 more
wiley   +1 more source

Impact of CALR and JAK2V617F Mutations on Clinical Course and Disease Outcomes in Essential Thrombocythemia: A Multicenter Retrospective Study in Turkish Patients

Turkish Journal of Hematology
Objective: In this study, we investigated the effects of calreticulin (CALR) and JAK2V617F mutational status on clinical course and disease outcomes in Turkish patients with essential thrombocythemia (ET).
Zehra Narlı Özdemir, Yıldız İpek, Püsem Patır, Gözde Ermiş, Rafiye Çiftçiler, Deniz Özmen, Mehmet Baysal, Vildan Gürsoy, Esra Yıldızhan, Serkan Güven, Tarık Ercan, Tayfun Elibol, Sinan Mersin, Eylem Genç, Eren Arslan Davulcu, Volkan Karakuş, Nergiz Erkut, Gürsel Güneş, Reyhan Diz Küçükkaya, Ahmet Emre Eşkazan   +19 more
doaj   +1 more source

The effects of mutational profiles on phenotypic presentation of myeloproliferative neoplasm subtypes in Bosnia: 18 year follow-up

Biomolecules & Biomedicine, 2020
The identification of mutually exclusive somatic mutations shared among myeloproliferative neoplasm (MPN) subtypes has provided a powerful tool for studying disease evolution.
Amina Kurtovic-Kozaric, Erna Islamagic, Hana Komic, Nurija Bilalovic, Izet Eminovic, Adnan Burekovic, Amna Uzunovic, Sabira Kurtovic   +7 more
doaj   +1 more source

Current Issues of Targeted Therapy of Polycythemia Vera

Клиническая онкогематология, 2021
The issues of therapy response criteria, first-line hydroxycarbamide intolerance and resistance to it as well as early changes in treatment strategy remain controversial and debatable in the management of polycythemia vera patients.
Anait Levonovna Melikyan, I. N. Subortseva   +1 more
doaj   +1 more source

Ruxolitinib Pharmacokinetics and Exposure–Toxicity Relationship in Hematologic Malignancies and Immune‐Mediated Diseases: A Prospective Observational Study

Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 753-761, September 2026.
Ruxolitinib pharmacokinetics (PK) has been characterized in clinical trials but remains poorly documented in real‐world practice. This project aimed to investigate ruxolitinib PK in routine clinical practice, identify factors driving its variability, and explore exposure–response relationships to assess the potential role of therapeutic drug monitoring.
Jérémie Tachet, Sara C. Meyer, Francesco Grandoni, Emmanuel Haefliger, Monika Nagy‐Hulliger, Jörg P. Halter, Jakob R. Passweg, David Haefliger, Carine Bardinet, Laurent A. Decosterd, Monia Guidi, François R. Girardin   +11 more
wiley   +1 more source

Pain Management in Erythromelalgia: A Systematic Review and Graded Appraisal Across Etiological Subtypes

European Journal of Pain, Volume 30, Issue 8, September 2026.
ABSTRACT Introduction Erythromelalgia is a rare disorder characterised by burning pain, erythema and increased skin temperature in the extremities. Its pathophysiological heterogeneity, together with variable treatment responses, complicates management in the absence of evidence‐based guidelines.
Camille Racca, Sarah Berthelot, Julia Franken, Marion Licois, Ada Du Pasquier, Ihssene Djidjeli, Laura Esteve, Eric Serra, Xavier Moisset   +8 more
wiley   +1 more source